Pieris Pharmaceuticals, Inc. Forecast, price target & analysts
Pieris Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Pieris Pharmaceuticals, Inc. Classifications & Recommendation:
Pieris Pharmaceuticals, Inc. Price Target
| Target Price | $37.75 |
| Price | $18.85 |
| Potential |
100.27%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .
The average Pieris Pharmaceuticals, Inc. target price is $37.75.
This is
100.27%
register free of charge
$44.00
133.42%
register free of charge
$30.00
59.15%
register free of charge
|
|
| A rating was issued by 4 analysts: 4 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of
100.27%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.81 | 0.03 |
| 65.29% | 99.94% |
4 Analysts have issued a sales forecast Pieris Pharmaceuticals, Inc. 2024 . The average Pieris Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| EV/Sales | 7,462.52 |
Based on analysts' sales estimates for 2024, the Pieris Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Pieris Pharmaceuticals, Inc....
Current Pieris Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 26 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 20 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 11 2025 |
| TD Cowen | Locked ➜ Locked | Locked | Feb 05 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 10 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 03 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 26 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
TD Cowen: Locked ➜ Locked
|
Feb 05 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 03 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 26 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
